AVORO CAPITAL ADVISORS LLC 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 09:34 am Sale | 2024-09-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS | AVORO CAPITAL ADVISORS LLC | 0 0.000% | -3,150,000 (Position Closed) | Filing |
| 2024-02-14 09:04 am Unchanged | 2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | AVORO CAPITAL ADVISORS LLC | 3,150,000 5.800% | 0 (Unchanged) | Filing |
| 2023-02-14 09:36 am Sale | 2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | AVORO CAPITAL ADVISORS LLC | 3,150,000 6.300% | -85,000 (-2.63%) | Filing |
| 2022-02-11 10:01 am Purchase | 2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | AVORO CAPITAL ADVISORS LLC | 3,235,000 8.800% | 2,858 (+0.09%) | Filing |
| 2021-02-12 08:14 am Purchase | 2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | AVORO CAPITAL ADVISORS LLC | 3,232,142 9.090% | 3,232,142 (New Position) | Filing |